NOVO-NORDISK A-S-SPONS ADR live chart 106.382.256 % ↓ Swap Short: -3.1808 % Swap Long: -2.8597 % Sell 106.13 ↑ 25 Buy 106.38 ↑ Low: 104.42 Spread MT5 floating High: 108.58 Past performance is not a guarantee or prediction of future performance. ...
SHARE Magazine UK|SHARE Magazine DK Index Message from the CEO Novo Nordisk launches initiative to tackle childhood obesity EU regulators recommend Wegovy® label update to include heart failure benefits ESSENCE trial showcases semaglutide’s potential in MASH ...
Danish drugmaker Novo Nordisk (NYSE:NVO) has been reprimanded (an official statement of disapproval) by UK regulators for not disclosing around £7.8 million ($9.97 ...
Latest Novo Nordisk A/S (NVON:MEX) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
Denmark's Novo Nordisk, the world's top insulin maker, said Friday it has acquired a British firm that is pioneering a new technology which could help people with diabetes inject themselves more safely with insulin.
Novo Nordisk A/S - share repurchase programmeJan. 20GL Ozempic, Wegovy and other new drugs are selected for Medicare's price negotiationsJan. 17AQ Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence...
NOVO NORDISK Price(1m / 3m / 12m): -3.3%/-20.9%/-22.1% LAST CLOSE: DKK603.7 TARGET PRICE: OVERVIEW Novo was probably the world's leading diabetes company, but nobody cares anymore. After getting their weekly T2D jab, Ozempic, approved for obesity as Wegovy in... (guest preview ends)...
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 13 September 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 12,235,249 B shares at an average share price of DKK 881.30 per B...
The Investor portal is for you as a Novo Nordisk shareholder. View your personal share information, register to receive Novo Nordisk Annual Report and Annual General Meeting notification, and change your contact information. Contact Investor Relations ...
Novo Nordisk also agreed to acquire the asset Ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences PTE., Ltd. in 2023. The purchase price of the asset acquisition was USD 800 million with additional contingent payments of USD ...